
XORTX Grants Options
CALGARY, Alberta, Jan. 12, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has granted in accordance with the Company’s stock option plan an aggregate of 700,000 options to purchase common shares of the Company to a consultant and a director of the Company.
› Read more